MYCN and neoplasm: (2) Secondly, from the patients' view, many patients' parents, including many recruited patients' parents in this study, are unwilling to choose these genomic tests (detections of MYCN status and 11q aberration) due to the expensive costs of fluorescence in situ hybridization (FISH) technology and relatively hard-to-obtain sample requirements (fresh tumor specimens or bone marrow samples).